# Biomarkers, Labs, and Imaging Support for Precision Medicine

## Overview
This implementation addresses the critical requirements for biomarker testing, laboratory measurements, and imaging assessments in modern precision medicine. It leverages OMOP's measurement table foundation while extending it with specialized models for comprehensive molecular profiling including tumor mutational burden (TMB), PD-L1 expression, MSI status, HER2 testing, and ER/PR status.

## Key Enhancements

### 1. Enhanced Choice Classes

#### **ImagingModalityChoices**
- CT, MRI, PET, PET/CT, Ultrasound, X-Ray, Mammography, Nuclear Medicine, Fluoroscopy, Angiography

#### **BiomarkerCategoryChoices**
- Protein Expression, Genomic Alteration, Immune Marker, Metabolic Marker, Tumor Burden, Hormone Receptor, Growth Factor Receptor

#### **LabTestCategoryChoices**  
- Hematology, Clinical Chemistry, Immunology, Molecular Diagnostics, Tumor Markers, Coagulation, Endocrine, Cardiac Markers

#### **TumorResponseChoices**
- Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Not Evaluable (NE), Mixed Response (MR)

### 2. OMOP Imaging Extension

#### **ImagingStudy Model**
- **DICOM Integration**: Study UID, accession number, DICOM availability
- **Modality Support**: All major imaging modalities with contrast tracking
- **Clinical Context**: Indication, referring physician, imaging study tracking
- **Quality Assessment**: Image quality scoring, artifact detection
- **Response Assessment**: Baseline imaging, follow-up imaging, measurement tracking

#### **ImagingMeasurement Model**
- **RECIST Compliance**: Target/non-target lesion tracking, response categories
- **Quantitative Measurements**: Longest diameter, perpendicular diameter, volume
- **Anatomical Context**: Region specification, laterality support
- **Biomarker Integration**: Enhancement patterns, signal intensity, perfusion parameters
- **Quality Assurance**: Measurement confidence, reader identification

### 3. Enhanced Measurement Model

#### **Laboratory Test Support**
- **LOINC Integration**: Standard LOINC codes for laboratory tests
- **Test Categorization**: Lab test categories and organ system classification
- **Clinical Context**: Safety parameters, baseline values, therapeutic monitoring
- **Quality Indicators**: Delta check, panic values, interference flags (hemolysis, lipemia, icterus)
- **Therapeutic Drug Monitoring**: Drug concentrations, therapeutic ranges

#### **Biomarker Enhancement**
- **Molecular Biomarker Types**: Protein, genomic, metabolic classifications
- **Clinical Interpretation**: Standardized result interpretation fields
- **Assay Context**: Method specification, reference ranges

### 4. Clinical Trial Biomarker Model

#### **Key Biomarkers Supported**
- **TMB (Tumor Mutational Burden)**: Numeric values with threshold assessments
- **PD-L1 Expression**: Percentage scoring with clinical cutoffs
- **MSI Status**: MSI-High/Low/MSS classifications
- **HER2 Testing**: IHC (0, 1+, 2+, 3+) and FISH (amplified/not amplified)
- **Hormone Receptors**: ER/PR status with percentage scoring
- **Other Key Markers**: TIL, BRCA status, NTRK fusions, CDK4/6, PI3K/AKT

#### **Testing Methodology**
- **Assay Standardization**: IHC, FISH, NGS, PCR, WES, WGS, Flow Cytometry, ELISA
- **Quality Assurance**: Laboratory certification, quality scoring
- **Companion Diagnostics**: FDA-approved assay tracking

#### **Clinical Applications**
- **Threshold Management**: Clinical cutoffs with assessments
- **Therapeutic Targets**: Links to drug targets and therapeutic options
- **Companion Diagnostics**: FDA-approved assay tracking

### 5. Clinical Lab Test Model

#### **Comprehensive Lab Testing**
- **Organ System Classification**: Hepatic, renal, cardiac, hematologic, metabolic, immunologic, endocrine
- **CTCAE Grading**: Grades 0-5 for toxicity assessment
- **Reference Ranges**: Normal ranges with abnormal flagging (H, L, HH, LL, A)
- **Clinical Context**: Safety monitoring, baseline assessments, therapeutic monitoring

#### **Quality Assurance**
- **Specimen Quality**: Hemolysis, lipemia, icterus flagging
- **Processing Metrics**: Processing delays, collection methods
- **Analyzer Tracking**: Equipment and methodology documentation

### 6. Curated Biomarker Vocabulary

#### **Standardization Framework**
- **Multiple Code Systems**: LOINC, SNOMED, HGNC integration
- **Site-Specific Mappings**: Local codes and reference ranges
- **Evidence Levels**: FDA approved to investigational classifications

#### **Clinical Utility**
- **Therapeutic Applications**: Common treatment selection criteria, stratification factors
- **Companion Diagnostics**: FDA-approved biomarker-drug combinations
- **Cancer Type Specificity**: Applicable cancer type documentation

#### **Threshold Standardization**
- **Clinical Cutoffs**: Positive/high expression thresholds
- **Assay Preferences**: Preferred and validated assays
- **Quality Evidence**: Evidence levels for clinical utility

## OMOP Compliance and Standards

### 1. LOINC Integration
- Direct LOINC code mapping for laboratory tests
- Standardized units and reference ranges
- Quality indicator standardization

### 2. SNOMED Integration
- Clinical concept mapping for biomarkers
- Anatomical site standardization
- Clinical significance terminology

### 3. DICOM Standards
- Study UID integration for imaging
- Modality standardization
- Image quality assessment

### 4. RECIST Compliance
- Target lesion tracking
- Response assessment standardization
- Measurement methodology

## Benefits for Precision Medicine

### 1. Automated Therapeutic Matching
- Standardized biomarker thresholds enable automated treatment selection
- CTCAE grading supports safety assessments
- Lab value ranges facilitate therapeutic monitoring

### 2. Response Assessment
- RECIST-compliant tumor measurements
- Standardized response categories
- Longitudinal tracking capabilities

### 3. Safety Monitoring
- Comprehensive lab test tracking with CTCAE grading
- Real-time safety parameter monitoring
- Quality-assured measurements

### 4. Biomarker-Guided Treatment
- Standardized biomarker categories
- Threshold-based treatment selection
- Companion diagnostic integration

### 5. Data Harmonization
- OMOP-compliant structure for cross-study analysis
- Standardized vocabularies for data integration
- Quality-assured measurements for reproducibility

## Future Extensions

### 1. AI/ML Integration
- Standardized imaging measurements for AI training
- Quality-assured biomarker data for ML models
- Longitudinal data for predictive modeling

### 2. Real-World Evidence
- Standardized measurements for RWE studies
- Quality indicators for data reliability
- Longitudinal biomarker tracking

### 3. Precision Medicine
- Comprehensive molecular profiling support
- Multi-biomarker integration
- Therapeutic response prediction

This implementation transforms OMOP into a comprehensive platform for modern precision medicine biomarker and imaging requirements while maintaining full standards compliance and enabling seamless data integration across studies and institutions.
